Commonwealth of Pennsylvania Public School Empls Retrmt SYS Increases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 14.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,250 shares of the medical equipment provider’s stock after buying an additional 6,326 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Hologic were worth $3,418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the company. Canada Pension Plan Investment Board lifted its position in shares of Hologic by 131.2% during the 3rd quarter. Canada Pension Plan Investment Board now owns 396,532 shares of the medical equipment provider’s stock valued at $27,519,000 after buying an additional 225,000 shares in the last quarter. Campbell & CO Investment Adviser LLC lifted its stake in shares of Hologic by 3.5% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 7,893 shares of the medical equipment provider’s stock worth $548,000 after acquiring an additional 265 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Hologic by 1.0% in the third quarter. State Board of Administration of Florida Retirement System now owns 298,564 shares of the medical equipment provider’s stock worth $20,720,000 after purchasing an additional 2,947 shares during the period. Pathstone Family Office LLC lifted its position in shares of Hologic by 96.0% during the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after purchasing an additional 4,542 shares during the last quarter. Finally, Tealwood Asset Management Inc. boosted its stake in shares of Hologic by 2.4% during the third quarter. Tealwood Asset Management Inc. now owns 15,679 shares of the medical equipment provider’s stock valued at $1,088,000 after purchasing an additional 367 shares during the period. Institutional investors own 92.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Needham & Company LLC boosted their price target on Hologic from $83.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 2nd. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Morgan Stanley cut their price target on Hologic from $86.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, November 13th. UBS Group lifted their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Finally, Royal Bank of Canada dropped their target price on shares of Hologic from $74.00 to $72.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $86.89.

Read Our Latest Stock Report on HOLX

Hologic Stock Up 0.8 %

NASDAQ:HOLX opened at $74.06 on Tuesday. The company’s 50-day simple moving average is $72.20 and its 200-day simple moving average is $71.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The stock has a market capitalization of $17.38 billion, a P/E ratio of 35.10, a P/E/G ratio of 2.48 and a beta of 1.02.

Hologic (NASDAQ:HOLXGet Free Report) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue was down 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.07 earnings per share. On average, equities analysts anticipate that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Insider Activity at Hologic

In other news, Director Scott T. Garrett sold 10,000 shares of Hologic stock in a transaction on Monday, December 11th. The shares were sold at an average price of $68.71, for a total transaction of $687,100.00. Following the completion of the sale, the director now directly owns 47,039 shares in the company, valued at $3,232,049.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Hologic news, Director Scott T. Garrett sold 10,000 shares of Hologic stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $68.71, for a total transaction of $687,100.00. Following the completion of the sale, the director now directly owns 47,039 shares in the company, valued at approximately $3,232,049.69. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Essex D. Mitchell sold 7,500 shares of the stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $71.85, for a total transaction of $538,875.00. Following the completion of the sale, the insider now owns 12,827 shares in the company, valued at approximately $921,619.95. The disclosure for this sale can be found here. Insiders have sold 32,440 shares of company stock valued at $2,346,475 in the last ninety days. Corporate insiders own 1.75% of the company’s stock.

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.